Journal of Cardiovascular Pharmacology

JANUARY 8, 2024

From inception until August 2023, we systematically searched five public literature databases to conduct the umbrella review. The favorable efficacy of CHM was primarily presented on five main conditions, coronary artery disease, hypertension, heart failure, restenosis, and angina pectoris.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease Angina Heart Failure 40

DAIC

FEBRUARY 29, 2024

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

DAIC

JANUARY 23, 2024

As of June 2023, the U.S. mg experienced a 23% lower incidence of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization in a time-to-event analysis. Accessed November 8, 2023. Accessed January 18, 2023.

Cardiovascular Disease 111

Cardiovascular Disease Heart attacks Heart Attack Coronary Artery Disease 111